Navigation Links
BioRelix and Dalton Medicinal Chemistry Expand and Renew Research Agreement to Capitalize on Riboswitches
Date:3/23/2009

BioRelix, pioneers in the discovery and development of Riboswitch based therapeutic agents, and Dalton Medicinal Chemistry have jointly announced an expansion and renewal of their exclusive worldwide collaboration and agreement to discover and develop new therapeutics.

New Haven, CT and Toronto, Canada (PRWEB) March 23, 2009 -- BioRelix, pioneers in the discovery and development of Riboswitch based therapeutic agents, and Dalton Medicinal Chemistry have jointly announced an expansion and renewal of their exclusive worldwide collaboration and agreement to discover and develop new therapeutics.

Dalton Medicinal Chemistry will apply their proprietary insights to the design and synthesis of new classes of compounds against selected Riboswitch targets. BioRelix will advance these compounds with their cutting edge array of biological assays and thorough knowledge of Riboswitch drug discovery and development.

Brian Dixon, BioRelix CEO commented, "We are pleased to have the opportunity to expand and renew our productive relationship with the creative team at Dalton Medicinal Chemistry. We are confident their expertise, insights and commitment to high quality medicinal chemistry, coupled with our propriety and leading position on Riboswitches, will continue to deliver value in important new medicines."

Judd Berman, Co-founder of Dalton Medicinal Chemistry, said: "We are delighted to work further with BioRelix in the discovery and development of much needed new anti-infective agents. The team at BioRelix has clearly established a remarkably innovative and fundamentally groundbreaking approach to anti-infectives and we are pleased to be with them at the forefront of this medicinal chemistry and drug discovery."

About BioRelix:
BioRelix, Inc. is a drug discovery and development company focused on identifying new anti-infective drug treatments. BioRelix is building a portfolio of anti-infective product candidates based on novel patented RNA targets, termed Riboswitches, which were identified by the laboratory of BioRelix co-founder, Ronald Breaker, Ph.D., Howard Hughes Investigator and Henry Ford II Professor at Yale University. BioRelix investors include CHL Medical Partners, Novartis Venture Fund, Aisling Capital, New Leaf Venture Partners, Elm Street Ventures and Alexandria Real Estate Equities.

About Dalton Medicinal Chemistry:
Dalton Medicinal Chemistry is a drug discovery company focused on the design, synthesis and advancement of new chemical entities in partnership with Biotech and Pharma.

Contacts:
BioRelix, Inc.
Brian Dixon
203-785-9282
www.biorelix.com

Dalton Medicinal Chemistry
Peter Pekos
416-661-2102
www.dalton.com

###

Read the full story at http://www.prweb.com/releases/BioRelix/Dalton_Medicinal/prweb2255524.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

Related medicine news :

1. PartsSource President & CEO A. Ray Dalton Wins Innovation in Business Award
2. PartsSource President & CEO A. Ray Dalton Named Harvard School of Business Entrepreneur of the Year
3. Bruker Daltonics Showcasing Novel Proteomics Solutions Based on Mass Spectrometry at the 7th HUPO World Congress 2008
4. Dalton Pharma Services and Boehringer Ingelheim (Canada) Ltd. Announce the Renewal of their Chemistry Services Agreement
5. Non-medicinal treatment touted for pre-schoolers with ADHD
6. Nonmedicinal treatment touted for preschoolers with ADHD
7. ATIR Classified as "Cell Based" Medicinal Product by the EMEA
8. Indian medicinal plant Acanthus ilicifolius may combat liver cancer
9. Oriental Medicinal Herb Garden Dedication
10. An Alternative to Medicinal Marijuana
11. MS drug development agreement based on WEHIs medicinal chemistry
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
BioRelix and Dalton Medicinal Chemistry Expand and Renew Research Agreement to Capitalize on Riboswitches 
(Date:4/29/2016)... ... ... On Tuesday, April 26, 2016 members of the HomeTown Health network, a ... Deal on SB 258, the “Rural Health Care Relief” Bill. , The bill, which ... to individuals and corporations which donate directly to a “rural hospital” in Georgia, and ...
(Date:4/29/2016)... ... April 29, 2016 , ... The White House ... their loans, more information about their loan terms and accounts, and more protections ... debt, including federal and private loans, has reached $1.3 trillion, with 43 million ...
(Date:4/29/2016)... ... April 29, 2016 , ... A ... born with severe congenital diaphragmatic hernia have better survival rates if surgery is ... hernia (CDH)—a condition where the diaphragm fails to form completely, letting abdominal organs ...
(Date:4/29/2016)... ... 2016 , ... Mobility Designed is redefining mobility with their patent pending ... Crutch evenly distributes body weight from the elbow to the forearm. In consumer ... than with other crutches. , Co-founders Max and Liliana Younger were inspired to design ...
(Date:4/29/2016)... (PRWEB) , ... April 29, 2016 , ... Melanoma is the deadliest type of skin ... blame for the majority of skin cancer deaths. More than 10,000 people are expected to ... at diagnosis is 62, it is the one of the most commonly diagnosed cancers in ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... , April 28, 2016 Oramed Pharmaceuticals ... clinical-stage pharmaceutical company focused on the development of oral drug ... the upcoming PIONEERS 2016 conference, presented by Joseph Gunnar ... in New York . Nadav Kidron ... the conference. Presentation Details:   ...
(Date:4/28/2016)... New market research titled ... report that provides an overview of the Osteoarthritis,s ... identifying new targets and MOAs to produce first-in-class ... in this H1 2016 Osteoarthritis Pipeline report include ... Abiogen Pharma S.p.A., Ablynx NV, Achelios Therapeutics, Inc., ...
(Date:4/27/2016)... , April 27, 2016   ... 42% Growth in Recurring Consumable Sales  Clinical ... Mauna Kea Technologies (Euronext: MKEA, OTCQX: MKEAY) inventor of ... its sales for the first quarter ended March 31, ... the execution of its commercial strategy. First ...
Breaking Medicine Technology: